1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Phoqus Pharmaceuticals nears the end

 
• By Christopher Spillane

[C#199901955:Phoqus] Pharmaceuticals faces the ignominy of winding down its operations or selling itself after trading of its shares on AIM were suspended. The firm's failure to secure a commercial partner for its lead candidate, Chronocort, preceded the suspension.

Phoqus Pharmaceuticals faces the ignominy of winding down its operations or selling itself after trading of its shares on AIM were suspended. The firm's failure to secure a commercial partner for its lead candidate, Chronocort, preceded the suspension.

The UK company said that its partnering discussions for the candidate "ceased without success" and now it would consider its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

More from Therapeutic Category

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.